DxS's disclosure last week that Bayer Diagnostics would license its ARMS genotyping technology was the first deal of its kind the British company has announced since obtaining rights to commercialize the tool from AstraZeneca nearly 16 months ago.

The deal, which is a three-way agreement between Bayer Diagnostics, DxS, and British patent enforcer BTG, gives Bayer the right to use the mutation-detection tool to develop certain undisclosed assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.